English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 28 January 2021, 09:50 HKT/SGT
Share:
China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter
China's first and only CAR-T product with CD20 target approved for registration clinical application

HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007 Cellular Injection on January 21, 2021, which is registered as a Class I new drug. LY007 Cellular Injection is mainly used for the treatment of non-Hodgkin lymphoma. It is currently the first and only CD20-targeted CAR-T product whose application for a registered clinical trial has been approved in China.

LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has beenwas developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal.The National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.

According to a research report issued by China Merchants Bank on CH BIOTECH SER on November 20, 2020, the analyst recommended to watch for the results of the LY007 Cellular Injection clinical trial which could enhance the company's market value. The report also pointed out that the company's current market capitalization is slightly less than US$200 million while market capitalization of CAR-T comparable companies listed on the main board of the Hong Kong Stock Exchange is between US$600 million and US$1.4 billion. The current market value of CAR-T comparable Chinese companies listed on NASDAQ is approximately US$3.5 billion.


Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Typhoon special arrangements for Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks  
July 19, 2025 21:09 HKT/SGT
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis  
July 18, 2025 21:00 HKT/SGT
Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit  
July 18, 2025 17:00 HKT/SGT
Doubleview Gold Corp Provides Comprehensive Update on Its Flagship Project - the Polymetallic Hat Deposit  
July 18, 2025 14:09 HKT/SGT
Honda Koraidon First Showrun during Suzuka 8 Hours
  
Friday, July 18, 2025 10:06:00 AM
SJC2 optical submarine cable in operation  
Friday, July 18, 2025 8:36:00 AM
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability  
July 18, 2025 00:05 HKT/SGT
Belgian Aircrew Completes MQ-9B Training  
July 18, 2025 00:05 HKT/SGT
A New Transatlantic Partnership for European CCA  
July 18, 2025 00:00 HKT/SGT
IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today  
July 17, 2025 20:32 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575